Objective: Previous studies involving large administrative data sets have revealed regional variation in the demographics of patients selected for carotid endarterectomy (CEA) and carotid artery stenting (CAS) but lacked clinical granularity. This study aimed to evaluate regional variation in patient selection and operative technique for carotid artery revascularization using a detailed clinical registry.
Carotid artery revascularization is one of the most commonly performed procedures, with >250,000 performed annually worldwide. 1 Much like with other common vascular procedures, such as abdominal aortic aneurysm repair, previous studies have identified wide variation in patient selection and treatment in these populations. [2] [3] [4] Carotid endarterectomy (CEA) has long been the standard approach; however, there has recently been increased implementation of the less invasive alternative, carotid artery stenting (CAS). 5 Previous studies using administrative databases have identified a trend toward increasing use of CAS and have shown significant geographic variation within it. 6, 7 According to Birkmeyer et al, variation itself falls into two major categories: acceptable and unwarranted. 8 Acceptable variation includes variables such as patient comorbidities and operative techniques for which guidelines are unclear or do not exist. Unwarranted variation reflects areas in which best-practice measures have been created and guidelines are in place to serve as benchmarks for quality care. They reviewed a number of common surgical procedures, including CEA, and determined that discretion of the clinician was the largest factor responsible for variation.
The Dartmouth Atlas evaluated trends in variation, specifically in carotid revascularization, and showed that although there was an increasing use of CAS, there was significant regional variation in its application. 9 Additional research involving Medicare patients corroborated these results and showed a high degree of variability in practice patterns. 4, 10 This study builds on those previously performed by providing additional data, such as operative details, that the others were lacking. With the evolution in health care management and greater focus on consistency in quality patient care, there has been a rising interest in establishing solid, evidencebased benchmarks to guide physician care. The Society for Vascular Surgery (SVS) has identified such standards for carotid revascularization procedures. 11, 12 These pertain to patient factors, such as the recommendation for medical management in asymptomatic patients with stenosis <60%. In addition, they have developed technical considerations, such as when to use CEA over CAS, the use of a patch during CEA, and the use of a protection device during CAS. Although these guidelines exist, limited data are available about how routinely they are being used.
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Despite the variation in use of CAS, limited data have shown the variation in patient selection, operative technique, and indications for intervention for carotid disease. Moreover, few studies have assessed how treatment compares with current quality benchmarks. We hypothesized that significant variation exists across the regions with regard to patient selection and treatment of carotid artery revascularization. Therefore, this study aimed to evaluate the regional variation in baseline patient characteristics and comorbidities, indications for treatment, procedure selection, and operative characteristics. Furthermore, we aimed to compare current practice with those clinical benchmarks established by the SVS. By evaluating the variation surrounding these factors, we identified areas in which quality improvement efforts can focus on adherence to existing current guidelines as well as direct further research to define best practices.
METHODS
Database. The Vascular Quality Initiative (VQI) was used to identify all patients who underwent CEA or CAS from 2009 to 2015. The VQI is a national clinical registry developed by the SVS to help improve patient care. It represents a collaboration between 17 deidentified regional quality groups, involving >300 hospitals and 1300 physicians. Additional information regarding the registry can be found at www.vascularqualityinitiative.org/. The Beth Israel Deaconess Medical Center Institutional Review Board approved this study, and consent of the patient was waived because of the deidentified nature of this data set.
Variables. Variable definitions were set forth by the VQI and were not able to be altered. Patient demographics, comorbid conditions, preoperative medications, and operative details were identified for all patients. Symptomatic disease was defined as any history of ipsilateral ocular or cortical stroke or transient ischemic attack. The degree of stenosis was obtained from the ipsilateral internal carotid artery stenosis measurement. The modality to obtain this measurement is not listed in the registry.
SVS guidelines were then used to identify a subset of patients for whom CAS is preferred to CEA. This included symptomatic patients with stenosis >50% who were considered at high risk for anatomic reasons (high lesions, tracheal stoma, or a history of previous irradiation or ipsilateral surgery) or stenosis >50% and severe coronary artery disease, congestive heart failure, or chronic obstructive pulmonary disease.
Statistical analysis. Statistical analysis was conducted using SPSS Statistics version 23 (IBM Corp, Armonk, NY), and all figures were produced using GraphPad version 6.0 (GraphPad Software Inc, La Jolla, Calif). c 2 analysis was used to compare variation across regions. Forest plots were used to represent the range of each variable across the 17 regions, depicted by a line containing symbols, each of which represents an individual region. Each region had a volume of >100 of either procedure, and therefore all were analyzed individually. The vertical line on each plot represents the VQI median. A P value of < .05 was considered statistically significant.
RESULTS
A total of 57,555 carotid artery revascularizations were performed, consisting of 49,179 CEA and 8376 CAS procedures.
Patient selection and demographics. As depicted in Recommendation: The authors suggest that quality improvement projects could be directed toward adherence to existing practice guidelines.
revascularization. Male patients underwent the majority of these interventions across all regions, with significant variation noted only in the CEA population (58%-63%; P ¼ .03). The proportion of asymptomatic CEA and CAS patients older than 80 years across regions ranged from 12% to 27% (P < .01) and 8% to 26% (P < .01), respectively. Wide variation was seen in the proportion of white patients, ranging from 80% to 96% (P < .01) in CEA and 71% to 97% (P < .01) in CAS. Patient comorbidities also reflected significant regional variation, including hypertension, diabetes mellitus, congestive heart failure, and chronic obstructive pulmonary disease. Smoking also varied widely across the regions (CEA, 60%-80% [P < .01]; CAS, 64%-81% [P < .01]). Before CAS, the use of preoperative computed tomography angiography or magnetic resonance angiography ranged from 31% to 83% (P < .01) across the regions.
Indications for procedure. The proportion of CEA and CAS procedures performed in asymptomatic patients ranged from 46% to 69% (P < .01) and 29% to 51% (P < .01), respectively (Fig 2) . Within this population, the proportion of interventions performed for stenosis <70% ranged from 3% to 9% (P < .01) for CEA and 3% to 22% (P < .01) for CAS (Fig 3) . In addition, revascularization of asymptomatic patients with a stenosis <60% ranged from 1% to 4% for CEA (P < .01) and 0% to 15% for CAS (P < .01; Fig 4) . Finally, using the SVS guidelines to define optimal CAS patients, we found wide variation across regions of these patients undergoing CEA instead (8%-18%; P < .01; Fig 5) .
Operative technique. Among CEA patients, significant variation was found across the regions in the use of protamine (32%-89%; P < .01), eversion (vs longitudinal) endarterectomy (1%-23%; P < .01), and use of patch with longitudinal endarterectomy (87%-99%; P < .01). The use of general anesthesia during CEA ranged from 82% to 98% (P < .01). Within the general anesthesia patients, significant differences were seen in routine shunt use (25%-83%; P < .01) vs selective shunt use (0.1%-17%; P < .01). Among patients with routine shunting, those who had electroencephalography varied (0%-26%; P < .01), as did those who had stump pressure measured (0%-20%; P < .01) and those who were not under general anesthesia (0%-9%; P < .01; Fig 6) .
During CAS, the proportion performed without use of a neurologic protection device ranged from 4% to 40% (P < .01) across regions. In addition, prestent arterial dilation and postdilation rates varied from 5% to 26% (P < .01) and 63% to 93% (P < .01), respectively. Open-cell stents (vs closed) were used 5% to 65% (P < .01) of the time (Fig 6) . The proportion of CEA and CAS patients receiving optimal medical therapy preoperatively, defined as both an antiplatelet and a statin, ranged from 53% to 77% and 62% to 80%, respectively (Fig 7) . Likewise, at discharge, the rates varied from 68% to 86% and 68% to 85% for CEA and CAS patients, respectively (Fig 8) .
DISCUSSION
In this study, we sought to review regional variation in carotid artery revascularization procedures across the United States and found wide variation present throughout the regions of the VQI. Although some of the variation can be classified as acceptable and used for future projects to determine best practices, some of it represents unwarranted variation based on existing practice guidelines.
SVS guidelines recommend medical management for asymptomatic patients with stenosis <60% or symptomatic patients with stenosis <50%. Randomized trials demonstrated not only a failure of the intervention to prevent strokes but also increased morbidity from the intervention compared with medical therapy. [13] [14] [15] [16] Despite these clearly set guidelines, there was significant variation in interventions performed on asymptomatic patients with stenosis <60%, with as many as 4% of CEA patients and 15% of CAS patients. Currently, reimbursement is not provided for CAS for asymptomatic patients if the stenosis is determined to be <70%. 17 Yet we found that in spite of this, between 3% and 22% of CAS patients fell into this category. Within the CEA population, previous literature supports performing a patch angioplasty or eversion endarterectomy as opposed to primary closure as well as the use of protamine to reduce bleeding complications. [18] [19] [20] However, our study identified wide variation in both practices. Similarly, during CAS, embolic protection devices are recommended to reduce the risk of embolization. [21] [22] [23] These events may represent unwarranted variation, where clear guidelines exist. The SVS guidelines additionally contain recommendations for procedure selection. Several studies have assessed the utility of CAS in asymptomatic patients; however, there have been conflicting data. Consequently, the current guidelines do not recommend stenting for asymptomatic patients. 12 Nonetheless, we found extensive regional variation in the use of CAS in the asymptomatic population. Because of conflicting data as well as recent studies such as the Asymptomatic Carotid Trial (ACT) I, there is controversy within these recommendations, and therefore this does not represent unwarranted variation. 24 The use of CAS in the treatment of asymptomatic carotid disease is currently being investigated in multiple trials, including Asymptomatic Carotid Surgery Trial (ACST) 2, and has become the number one high-impact clinical research priority. [25] [26] [27] Conversely, for the population of symptomatic patients, the SVS recommends CAS for symptomatic patients with stenosis >50% who are considered at high risk for anatomic reasons (high lesions, tracheal stoma, or a history of previous irradiation or ipsilateral surgery) or stenosis >50% and severe coronary artery disease, congestive heart failure, or chronic obstructive pulmonary disease. Significant variation is present here as well; however, this is a lower level recommendation and is more dependent on specific patient factors, and therefore it may be considered more acceptable variation. In CAS patients, there is a clear benefit for dual antiplatelet therapy. [28] [29] [30] [31] In CEA patients, the benefit of dual therapy compared with monotherapy is unclear; however, the use of both an aspirin and statin in both the CEA and CAS populations is considered optimal medical therapy. [32] [33] [34] [35] Consequently, the variation found in these areas is likely unwarranted. Certainly, a small amount of variation should be expected, as some patients may not tolerate the medications or may be noncompliant; however, these patients made up <1% of our population. Therefore, the degree of variation we discovered suggests that there are other factors involved, such as provider preferences. This study illustrates that profound variation, both acceptable and unwarranted, is present in patient selection and treatment of carotid artery revascularization procedures across the regions of the VQI. Previous research involving carotid disease in Medicare beneficiaries has shown that significant geographic differences exist for the treatment of this disease in the United States. 6, 36 Additional studies using large, administrative databases have noted regional variation in the rates of CEA vs CAS performed; these studies helped drive the randomized controlled trials that ultimately formed many of the current benchmark guidelines. 3, 8, [37] [38] [39] This study not only confirmed the results of the previous work but also gives us the ability to quantify several aspects of patient care, such as rates of adoption of best medical therapy, which show significant regional variation. This, in turn, helps define areas for research efforts designed to improve adherence to guidelines. Established metrics like protamine and patch use among patients undergoing CEA or protection device use during CAS could be targets for regional quality improvement projects. For those metrics with acceptable variation but without clear best practice, such as operative variables and the proportion of symptomatic to asymptomatic patients, the presence of variation shown in this study could serve as an impetus to begin research projects to identify best practices. In addition, even though these regions are all deidentified, each region, center, and surgeon have access to their own data and can act on their results. Contributors can use their own data to compare with others in their region and across the country. Furthermore, regional quality groups, such as the VQI, may choose to act further on areas where we have identified issues or provide direct feedback. We are currently working on the second part of this project, which investigates the regional variation in the outcomes of carotid revascularization. Pending the results of this project, there may be even more influence on quality groups to provide individualized feedback. This study has several important limitations to discuss. First, this is a retrospective analysis using prospectively collected data from the hospitals in the VQI. As is the case with large multicenter databases, there exists the potential for missing data and coding errors. To reduce these potential limitations, the VQI conducts an annual audit to review the clinical data submitted from the hospitals. In addition, the variables are set within the database by the VQI, and therefore we are unable to alter them to fit our study design. Given the deidentification of the data set, we are unable to evaluate variation among the different hospitals and surgeons within each region. In addition, we are unable to evaluate the potential influences of geographic location, such as being in highvolume urban regions vs rural areas. Aside from the database limitations, there is also natural geographic variation across populations of patients that we cannot account for, such as access to health care and local provider preferences. Prior work involving geographic variation has the same pitfalls, and the SVS guidelines have subsequently been developed without factoring this in as well. 3, 6, 9, 12, 36, 40 
CONCLUSIONS
This study identified multiple areas in patient selection and treatment of carotid artery disease in which significant variation exists, including procedure indications and operative techniques. In some of these areas, guidelines exist, and deviation from them is reflective of the variation in practice patterns we have found. In addition, there are still aspects of the care of patients with carotid disease that lack definitive evidence, and as such, future research is warranted. Quality improvement projects could be directed to improve adherence to guidelines that currently exist. We have identified targets for future research to determine additional best practices. 
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